30 results
6-K
EX-99.1
CMMB
Chemomab Therapeutics Ltd
3 May 24
Current report (foreign)
4:03pm
December 31, 2023, by our five (5) most highly compensated executive officers see Part III, Item 11 “Executive Compensation” of our Annual Report
6-K
EX-99.1
CMMB
Chemomab Therapeutics Ltd
3 Jul 23
Current report (foreign)
3:49pm
III, Item 11 “Executive Compensation” of our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 20, 2023 … on the compensation terms of Dr. Adi Mor, please see Part III, Item 11 “Executive Compensation” of our Annual Report.
The shareholders vote on this matter
8-K/A
4rqfyz7u
14 Apr 21
UNAUDITED PRO FORMA Condensed COMBINED FINANCIAL STATEMENTS
11:50am
424B3
ri6zftf
12 Feb 21
Prospectus supplement
12:05pm
S-4/A
x7ig dp6xb
10 Feb 21
Registration of securities issued in business combination transactions (amended)
1:19pm
S-4
xys2s
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
10-K
zhwb r31d
17 Mar 20
Annual report
5:27pm
6-K
EX-99.2
6rikfp iojtzb2vce2cp
28 May 19
Notice of Annual General Meeting of Shareholders of the Company
5:26pm
424B4
zrebgsdsh7ukno2lgctz
13 Feb 19
Prospectus supplement with pricing info
8:20am